Compare Logitech International SA (LOGI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Novartis AG — how do they compare? Logitech International SA trades at $98.15 (market cap $14.46B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 18.6× Logitech International SA's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Novartis AG for 82 Days on average.
| LOGI | NVS | |
|---|---|---|
Market Cap | $14.46B | $268.57B |
Volume | 349,547 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $126.69 | $168.62 |
52-Week Low | $85.84 | $121.80 |
Typical Hold Time | 92 Days | 82 Days |
Enterprise Value | $12.79B | $309.89B |
Dividend Yield | 1.63% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $98.27, down 3.83% over the past day, amid a neutral technical backdrop. The stock shows strong fundamental health with consistent earnings beats, a robust net income margin of 16.28%, and a forward P/E of 18.64. Recent product launches, including the Zone Vibe Pro headset and MX Keypad, highlight innovation in the hybrid work and gaming segments. Cash flow trends are positive, with 2026 operating cash flow projected at $1.1 billion, supporting dividend payments and growth initiatives.
The investment outlook is balanced. Upside is supported by solid profitability, strategic partnerships like the SEGA alliance, and analyst consensus target of $107. However, risks include competitive pressures in peripherals, sensitivity to consumer spending, and the stock's high P/B ratio of 6.18. Investor sentiment is mixed, with technical indicators neutral and analyst ratings evenly split between buy, hold, and sell.
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
